Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.21.2
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Costs and Operating Expenses        
Research and development expenses, excluding depreciation $ 57,638 $ 14,642 $ 96,956 $ 33,935
Selling, general and administrative expenses, excluding depreciation 44,625 3,411 100,252 7,492
Depreciation 2,083 1,756 4,207 3,441
Total costs and operating expenses 104,346 19,809 201,415 44,868
Loss from operations (104,346) (19,809) (201,415) (44,868)
Other (expense) income        
Interest income (expense) 34 (3,545) 46 (9,371)
(Loss) gain on fair value change in contingent earnout shares liability (8,157)   75,402  
Loss on fair value change in private placement warrants liability     (1,639)  
Other expense (income), net (85) 113 (174) 108
Loss before income taxes (112,554) (23,241) (127,780) (54,131)
Net loss and comprehensive loss $ (112,554) $ (23,241) $ (127,780) $ (54,131)
Per Share Data:        
Net loss per share, basic and diluted $ (0.50) $ (0.28) $ (0.57) $ (0.65)
Weighted-average shares outstanding, basic and diluted 226,928,000 83,739,513 225,885,000 82,845,081